Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...

Evenity is the first sclerostin inhibitor to be approved for osteoporosis, and is thought to work largely by encouraging the formation of new bone, with a lesser inhibitory effect on bone destruction.

Prolia sales missed the Zacks Consensus Estimate of $1.18 billion. Evenity recorded sales of $431 million in the quarter, up 36% year over year, driven by solid volume growth in the United States.